Overview
Sponsor-declared trial summary
Cardiovascular Disease
The primary objectives of this study is to demonstrate the superiority of pelacarsen (TQJ230) compared to placebo in reducing the risk of expanded MACE (cardiovascular death, non-fatal MI, non-fatal stroke and urgent coronary re-vascularization requiring hospitalization) in 1) the overall study population with establis…
Key facts
- Sponsor
- Novartis Pharma AG
- Participant type
- Patients
- Age range
- 18-64 years, 65+ years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Cardiovascular Diseases [C14]
- Trial duration
- 6 Mar 2020 → ongoing
- Decision date (initial)
- 2024-05-21
- Transition trial
- Yes
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- Yes
- Funding sources
- Novartis Pharma AG
External identifiers
- EU CT number
- 2023-508292-37-00
- EudraCT number
- 2019-001076-11
- ClinicalTrials.gov
- NCT04023552
Trial design
CTIS Part I — objectives, methods, condition coding
Main objective
Scope: Pharmacogenomic, Pharmacogenetic, Efficacy, Pharmacokinetic, Safety
The primary objectives of this study is to demonstrate the superiority of pelacarsen (TQJ230) compared to placebo in reducing the risk of expanded MACE (cardiovascular death, non-fatal MI, non-fatal stroke and urgent coronary re-vascularization requiring hospitalization) in 1) the overall study population with established CVD (Lp(a) ≥ 70 mg/dL) and/or 2) in a subpopulation with established CVD and Lp(a) ≥ 90 mg/dL.
Secondary objectives 4
- Demonstrate the superiority of pelacarsen (TQJ230) compared to placebo in reducing the risk of the MACE composite of CV death, non-fatal MI and non-fatal stroke.
- Demonstrate the superiority of pelacarsen (TQJ230) compared to placebo in reducing the risk of the composite of coronary heart disease (CHD) outcomes: death due to CHD, non-fatal MI and urgent coronary re-vascularization requiring hospitalization.
- Evaluate the rate of all cause death.
- Demonstrate the superiority of pelacarsen (TQJ230) compared to placebo in lowering the Lp(a) level at 1 year.
Conditions and MedDRA coding
Cardiovascular Disease
| Version | Level | Code | Term | System organ class |
|---|---|---|---|---|
| 21.1 | LLT | 10051614 | Arteriosclerotic cardiovascular disease | 10047065 |
Regulatory references
- Scientific advice from competent authorities
- European Medicines Agency
- Plan to share IPD
- Yes
Eligibility criteria
Principal inclusion / exclusion criteria as submitted by sponsor
Inclusion criteria 5
- Lp(a) ≥ 70 mg/dL at the screening visit
- Optimal LDL-cholesterol lowering treatment
- Myocardial infarction: ≥ 3 months from screening and randomization visits to ≤ 10 years prior to the screening visit, and/or
- Ischemic stroke: ≥ 3 months from screening and randomization visits to ≤ 10 years prior to the screening visit, and/or
- Clinically significant symptomatic peripheral artery disease
Exclusion criteria 8
- Uncontrolled hypertension
- Heart failure New York Heart Association (NYHA) class IV
- History of malignancy of any organ system
- History of hemorrhagic stroke or other major bleeding
- Platelet count <140,000 per mm3
- Active liver disease or hepatic dysfunction
- Significant kidney disease
- Pregnant or nursing women
Endpoints
Primary and secondary outcome measures (English text)
Primary endpoints 2
- Time to the first occurrence of CEC confirmed expanded MACE (cardiovascular death, nonfatal MI, non-fatal stroke and urgent coronary re-vascularization requiring hospitalization) in a population of patients with elevated Lp(a) ≥ 70 mg/dL
- Time to the first occurrence of CEC confirmed expanded MACE (cardiovascular death, non-fatal MI, non-fatal stroke and urgent coronary re-vascularization requiring hospitalization) in a subpopulation of patients with elevated Lp(a) ≥ 90 mg/dL
Secondary endpoints 4
- Time to the first occurrence of the CEC confirmed composite endpoint of MACE (CV death, non-fatal MI, and non-fatal stroke)
- Time to the first occurrence of the CEC confirmed composite endpoint of CHD: CHD death, non-fatal MI, urgent coronary revascularization requiring hospitalization
- Change in Lp(a) in the log scale from baseline at 1 year
- Time to CEC confirmed all-cause death
Investigational products
Investigational medicinal products (IMPs), comparators, placebo, auxiliary
Test 1
PRD10213050 · Product
- Active substance
- Pelacarsen
- Pharmaceutical form
- SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
- Route of administration
- SUBCUTANEOUS USE
- Max daily dose
- 80 mg milligram(s)
- Max total dose
- 6000 mg milligram(s)
- Max treatment duration
- 75 Month(s)
- Authorisation status
- Not Authorised
- MA holder
- NOVARTIS PHARMA AG
- Paediatric formulation
- No
- Orphan designation
- No
Placebo 1
N/A · Product
- Other product name
- N/A
- Pharmaceutical form
- N/A
- ATC code
- N/A — N/A
- Marketing authorisation
- N/A
- MA holder
- N/A
- MA country
- Iceland
- Paediatric formulation
- No
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Novartis Pharma AG
- Sponsor organisation
- Novartis Pharma AG
- Address
- Lichtstrasse 35
- City
- Basel
- Postcode
- 4056
- Country
- Switzerland
Scientific contact point
- Organisation
- Novartis Pharma AG
- Contact name
- Novartis Pharma Arzneimittel GmbH
Public contact point
- Organisation
- Novartis Pharma AG
- Contact name
- Novartis Pharma Arzneimittel GmbH
Third parties 33
| Organisation | City, country | Duties |
|---|---|---|
| Eco-Abc Sp. z o. o. ORG-100046253
|
Belchatow, Poland | Other |
| Cleveland Clinic Foundation ORG-100028017
|
Cleveland, United States | Other |
| Jumo Health USA Inc. ORG-100044054
|
New Haven, United States | Other |
| Statmed Sp. z o.o. ORG-100047187
|
Golkow, Poland | Other |
| S & D Pharma Logistics BG EOOD ORG-100017521
|
Sofia, Bulgaria | Other |
| Kayentis ORG-100037894
|
Meylan, France | E-data capture |
| PRA Hellas CRO A.E. ORG-100048208
|
Nea Ionia, Greece | On site monitoring |
| Phardis S.r.l. ORG-100019559
|
Calvenzano, Italy | Other |
| Distica hf. ORG-100022309
|
Gardabaer, Iceland | Other |
| Specific Pharma A/S ORG-100015041
|
Copenhagen Sv, Denmark | Other |
| Icon Clinical Research Limited ORG-100008322
|
Dublin 18, Ireland | On site monitoring, Other |
| Movianto Belgium ORG-100012072
|
Aalst, Belgium | Other |
| Greenphire LLC ORG-100041621
|
King Of Prussia, United States | Other |
| Abf Pharmaceutical Services GmbH ORG-100014752
|
Vienna, Austria | Other |
| Opt-X-Pense Kft. ORG-100047138
|
Budaors, Hungary | Other |
| World Courier Bulgaria EOOD ORG-100050062
|
Sofia, Bulgaria | Other |
| Alliance Healthcare Romania S.R.L. ORG-100034371
|
Rudeni, Romania | Other |
| Freja Transport & Logistics AS ORG-100018845
|
Frogner, Norway | Other |
| IQVIA Limited ORG-100008655
|
Reading, United Kingdom | On site monitoring |
| Qualitymetric Incorporated LLC ORG-100044132
|
Johnston, United States | Other |
| Parexel International (IRL) Limited ORG-100022780
|
Dublin 2, Ireland | Other |
| Mag. Andreas Raffeiner GmbH ORG-100043223
|
Walding, Austria | Code 8 |
| IQVIA Limited ORG-100008655
|
Reading, United Kingdom | Interactive response technologies (IRT) |
| Parexel International (IRL) Limited ORG-100022780
|
Dublin 2, Ireland | Code 12 |
| Labcorp Central Laboratory Services LP ORG-100032236
|
Indianapolis, United States | Laboratory analysis |
| ADR Logistics Kft. ORG-100045267
|
Budaors, Hungary | Other |
| Opis S.r.l. ORG-100011127
|
Desio, Italy | Other |
| Oriola Sweden AB ORG-100011733
|
Molnlycke, Sweden | Code 14 |
| Movianto Slovensko s.r.o. ORG-100020628
|
Senec, Slovakia | Other |
| Eurofins Genomics Europe Applied Genomics GmbH ORG-100044499
|
Ebersberg, Germany | Other |
| SALUS Veletrgovina druzba za promet s farmacevtskimi medicinskimi in drugimi proizvodi d.o.o. ORG-100017689
|
Ljubljana, Slovenia | Other |
| Syneos Health Inc. ORG-100008382
|
Morrisville, United States | On site monitoring |
| RWS Life Sciences Inc. ORG-100042348
|
East Hartford, United States | Other |
Locations
20 EU/EEA countries · 296 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Austria | Ongoing, recruitment ended | 120 | 6 |
| Belgium | Ongoing, recruitment ended | 93 | 8 |
| Bulgaria | Ongoing, recruitment ended | 48 | 8 |
| Czechia | Ongoing, recruitment ended | 506 | 39 |
| Denmark | Ongoing, recruitment ended | 183 | 7 |
| France | Ongoing, recruitment ended | 84 | 13 |
| Germany | Ongoing, recruitment ended | 1,019 | 56 |
| Greece | Ongoing, recruitment ended | 50 | 8 |
| Hungary | Ongoing, recruitment ended | 138 | 15 |
| Iceland | Ongoing, recruitment ended | 50 | 2 |
| Italy | Ongoing, recruitment ended | 190 | 22 |
| Netherlands | Ongoing, recruitment ended | 662 | 25 |
| Norway | Ongoing, recruitment ended | 52 | 2 |
| Poland | Ongoing, recruitment ended | 125 | 11 |
| Portugal | Ongoing, recruitment ended | 48 | 3 |
| Romania | Ongoing, recruitment ended | 48 | 10 |
| Slovakia | Ongoing, recruitment ended | 239 | 37 |
| Slovenia | Ongoing, recruitment ended | 60 | 2 |
| Spain | Ongoing, recruitment ended | 365 | 19 |
| Sweden | Ongoing, recruitment ended | 37 | 3 |
| Rest of world
Russian Federation, Peru, Turkey, China, Switzerland, Australia, India, United States, Brazil, Japan, Guatemala, Israel, Taiwan, South Africa, United Kingdom, Colombia, Mexico, Argentina, Chile, Hong Kong, Korea, Republic of, Canada
|
— | 4,206 | — |
Investigational sites
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Austria | 2020-06-04 | 2020-06-04 | 2022-07-07 | ||
| Belgium | 2020-06-12 | 2020-06-12 | 2022-07-07 | ||
| Bulgaria | 2020-09-01 | 2020-09-01 | 2022-07-07 | ||
| Czechia | 2020-06-11 | 2020-06-11 | 2022-07-07 | ||
| Denmark | 2020-06-12 | 2020-06-12 | 2022-07-07 | ||
| France | 2021-09-17 | 2021-09-17 | 2022-07-07 | ||
| Germany | 2020-03-06 | 2020-03-06 | 2022-07-07 | ||
| Greece | 2021-02-04 | 2021-02-04 | 2022-07-07 | ||
| Hungary | 2020-06-30 | 2020-06-30 | 2022-07-07 | ||
| Iceland | 2020-07-15 | 2020-07-15 | 2022-07-07 | ||
| Italy | 2020-07-28 | 2020-07-28 | 2022-07-07 | ||
| Netherlands | 2020-06-03 | 2020-06-03 | 2022-07-07 | ||
| Norway | 2020-11-02 | 2020-11-02 | 2022-07-07 | ||
| Poland | 2020-10-26 | 2020-10-26 | 2022-07-07 | ||
| Portugal | 2020-08-05 | 2020-08-05 | 2022-07-07 | ||
| Romania | 2021-09-21 | 2021-09-21 | 2022-07-07 | ||
| Slovakia | 2020-06-08 | 2020-06-08 | 2022-07-07 | ||
| Slovenia | 2021-06-23 | 2021-06-23 | 2022-07-07 | ||
| Spain | 2020-09-24 | 2020-09-24 | 2022-07-07 | ||
| Sweden | 2020-10-28 | 2020-10-28 | 2022-07-07 |
Results and documents
Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial
Documents 180 files
Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.
| Type | Title | Version |
|---|---|---|
| Protocol (for publication) | D1_Protocol - Signature Page_1_English_Red | 14May2025 |
| Protocol (for publication) | D1_Protocol_2023-508292-37-00_1_English_Red | 6 |
| Protocol (for publication) | D1_Protocol_2023-508292-37-00_1_Greek_Red | 6 |
| Protocol (for publication) | D4_Patient-facing document - PRO_1_SE_English_Note to Assesor_NonRed | 15Nov2024 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_BE_English_NonRed | 11Feb2020 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_BG_English_Note to Assesor_NonRed | 18Jun2024 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_CZ_NonRed | 05May2022 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_DE_English_Note to Assesor_NonRed | 12.06.2024 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_DK_English_NonRed_T | v01 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_ES_Spain_NonRed | 13/Jan/20 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_FR_French_NonRed | v01 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_GR_English_Note to Assesor_NonRed | 11-Jun-24 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_HU_English_NonRed | v01 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_IS_English_Note to assessor_NonRed | 1.0 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_IT_English_NonRed | 01 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_NL_English_Note to Assesor_NonRed | V00 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_PL_English_Note to Assesor_NonRed | 28May2024 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_PT_English_NonRed | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_RO_English_Note to Assesor_NonRed | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_SE_English_Note to Assesor_NonRed | 01 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_SI_English_Note to Assesor_NonRed | 28May2024 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_SK_English_Note to Assesor_NonRed | V1 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Site_1_AT_English_Note to Assesor_NonRed | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements-Country_1_NO_English_Note to Assessor_NonRed | 01 |
| Subject information and informed consent form (for publication) | L1_ICF - Additional Biomarkers_1_FR_French_Red | V03.04.03 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregant participant or pregnant partner of participant_1_FR_French_NonRed | V05.06.00 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_AT_German_NonRed | v00.03 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_BE_Dutch_NonRed | v0.0a |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_BE_English_NonRed | v0.0a |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_BE_French_NonRed | v0.0a |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_BG_Bulgarian_NonRed | 3 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_BG_English_NonRed | 00.00 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_CZ_Czech_NonRed | V1 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_DE_German_NonRed | 00.00.02 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_DK_Danish_NonRed | V1 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_ES_Spanish_NonRed | 22Jul2019 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_GR_English_Red | 0.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_GR_Greek_Red | 0.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_HU_Hungarian_NonRed | v1.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_IS_Icelandic_NonRed | 00.00.04 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_IT_Italian_NonRed | 06.00.02 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_NL_Dutch_NonRed | V00000001 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_NO_Norwegian_NonRed | v00.00.03 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_PL_Polish_NonRed | v03 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_PT_Portuguese_NonRed | 1.01 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_RO_Romanian_NonRed | v1.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_SE_Swedish_NonRed | V1 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_SI_Slovenian_NonRed | 00.00.02 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_SK_Slovak_NonRed | V1 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_2_HU_Hungarian_NonRed | v1.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant partner of participant_1_BE_Dutch_NonRed | v04.01.02 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant partner of participant_1_BE_English_NonRed | v04.01.02 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant partner of participant_1_BE_French_NonRed | v04.01.02 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant partner of participant_1_IT_Italian_NonRed | 06.00.02 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_AT_German_NonRed | v00.04 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_BG_Bulgarian_NonRed | 3 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_BG_English_NonRed | 01.01 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_CZ_Czech_Red | v2.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_DK_Danish_NonRed | V2 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_ES_Spanish_NonRed | 03Oct2019 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_GR_English_Red | 0.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_GR_Greek_Red | 0.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_HU_Hungarian_Red | v1.1 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_PL_Polish_NonRed | v03 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_PT_Portuguese_NonRed | 1.01 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_RO_Romanian_NonRed | v1.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_SE_Swedish_NonRed | V2 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_SI_Slovenian_NonRed | 01.01.02 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_SK_Slovak_NonRed | V1 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_2_DK_Danish_NonRed | V3 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_2_HU_Hungarian_NonRed | v1.1 |
| Subject information and informed consent form (for publication) | L1_ICF - Home Nursing Service_1_HU_Hungarian_NonRed | v04.01.01 |
| Subject information and informed consent form (for publication) | L1_ICF - Home Nursing Service_1_IT_Italian_NonRed | 04.01.01 |
| Subject information and informed consent form (for publication) | L1_ICF - Home Nursing Service_1_PL_Polish_NonRed_T | 02 |
| Subject information and informed consent form (for publication) | L1_ICF - Home Nursing Service_1_SI_Slovenian_NonRed | 04.01.02 |
| Subject information and informed consent form (for publication) | L1_ICF - Home Nursing Service_2_HU_Hungarian_NonRed | v04.01.01 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_AT_German_Red | 06.07.01 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_BE_Dutch_Red | 06.07.07 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_BE_English_Red | 06.07.07 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_BE_French_Red | 06.07.07 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_BG_Bulgarian_Red | v06.07.11 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_BG_English_Red | v06.07 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_CZ_Czech_Red | 06.07.08 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_DE_German_Red | v05.06.04 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_DK_Danish_Red | v06.07.10 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_ES_Spanish_Red | v06.07.05 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_GR_English_Red | v05.06.06 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_GR_Greek_Red | v06.07.07 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_HU_Hungarian_Red | v06.07.06 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_IS_English_NonRed | 24Nov2025 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_IS_Icelandic_Red | 06.07.10 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_IT_Italian_Red | 06.07.09 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_NL_Dutch_Red | V05060601 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_NO_Norwegian_Red | v06.07.06 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_PL_Polish_Red | v09 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_PT_Portuguese_Red | 06.01 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_RO_Romanian_Red | 06.07.07 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_SE_Swedish_Red | 06.07.07 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_SI_Slovenian_Red | v06.07.04 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_SK_Slovak_Red | 06.07.07.M |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_2_DE_German_Red | v03.04.00 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_2_FR_French_Red | V03.04.03 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_2_German_Red | v06.07.00 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_2_HU_Hungarian_NonRed | v04.05.04 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_2_SE_Swedish_Red | 04.05.04 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_3_DE_German_Red | v04.05.01 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_3_FR_French_NonRed | v05.06.05 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_4_FR_French_NonRed | v05.06.05 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_Addendum_1_FR_French_Red | V05.06.05 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_Addendum_5_FR_French_Red | V06.07.06 |
| Subject information and informed consent form (for publication) | L1_ICF - Optional Assessment_1_CZ_Czech_Red | v3.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Optional Assessment_1_SK_Slovak_NonRed | V2 |
| Subject information and informed consent form (for publication) | L1_ICF - Optional treatment beyond disease progression_1_CZ_Czech_NonRed | V2 |
| Subject information and informed consent form (for publication) | L1_ICF - Optional treatment beyond disease progression_1_ES_Spanish_NonRed | v04.01.01 |
| Subject information and informed consent form (for publication) | L1_ICF - Optional treatment beyond disease progression_1_IT_Italian_NonRed | 06.00.02 |
| Subject information and informed consent form (for publication) | L1_ICF - Optional treatment beyond disease progression_1_SI_Slovenian_NonRed | 1 |
| Subject information and informed consent form (for publication) | L1_ICF - Optional treatment beyond disease progression_1_SK_Slovak_NonRed | V1 |
| Subject information and informed consent form (for publication) | L1_ICF - Optional treatment beyond disease progression_2_CZ_Czech_NonRed | V2 |
| Subject information and informed consent form (for publication) | L1_ICF - Parent Legal Guardian_1_FR_French_NonRed | V05.06.00 |
| Subject information and informed consent form (for publication) | L1_ICF - Pharmacokinetics_1_CZ_Czech_Red | v5.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Pharmacokinetics_1_SK_Slovak_NonRed | V2 |
| Subject information and informed consent form (for publication) | L1_ICF - Pharmacokinetics_2_CZ_Czech_NonRed | V5 |
| Subject information and informed consent form (for publication) | L1_ICF - Separate Data Protection Consent_1_CZ_Czech_NonRed | V 05.06.02 |
| Subject information and informed consent form (for publication) | L1_ICF - Separate Data Protection Consent_1_SK_Slovak_NonRed | V2 |
| Subject information and informed consent form (for publication) | L1_ICF - Separate Data Protection Consent_2_SK_Slovak_NonRed | V1 |
| Subject information and informed consent form (for publication) | L1_List of submitted documents Part II_2_HU_Hungarian_NonRed | 25Jun2025 |
| Subject information and informed consent form (for publication) | L1_List of submitted documents_1_HU_English_NonRed | 09Jul2024 |
| Subject information and informed consent form (for publication) | L1_Patient Card_1_HU_Hungarian_NonRed | v02 |
| Subject information and informed consent form (for publication) | L1_Subject Info Sheet or Other Info_1_AT_German_Red | 04 |
| Subject information and informed consent form (for publication) | L1_Subject Info Sheet or Other Info_1_FR_French_Red | v1.0 |
| Subject information and informed consent form (for publication) | L1_Subject Info Sheet or Other Info_1_IT_Italian_NonRed | 01.00 |
| Subject information and informed consent form (for publication) | L1_Subject Info Sheet or Other Info_1_NO_Norwegian_NonRed | 01 |
| Subject information and informed consent form (for publication) | L1_Subject Info Sheet or Other Info_2_FR_French_NonRed | 11Oct2022 |
| Subject information and informed consent form (for publication) | L1_Subject Info Sheet or Other Info_2_NO_Norwegian_NonRed | 01 |
| Subject information and informed consent form (for publication) | L1_Subject Info Sheet or Other Info_3_FR_French_NonRed | v02 |
| Subject information and informed consent form (for publication) | L1_Subject Info Sheet or Other Info_3_NO_Norwegian_NonRed | 01 |
| Subject information and informed consent form (for publication) | L1_Subject Info Sheet or Other Info_4_FR_French_NonRed | v02 |
| Subject information and informed consent form (for publication) | L1_Subject Info Sheet or Other Info_4_NO_Norwegian_NonRed | 01 |
| Subject information and informed consent form (for publication) | L2_ICF Procedure_1_AT_German_Red | 1 |
| Subject information and informed consent form (for publication) | L2_ICF Procedure_1_BG_Bulgarian_NonRed | 1 |
| Subject information and informed consent form (for publication) | L2_ICF Procedure_1_CZ_Czech_Red | V1 |
| Subject information and informed consent form (for publication) | L2_ICF Procedure_1_DK_English_NonRed_T | v01 |
| Subject information and informed consent form (for publication) | L2_ICF Procedure_1_ES_Spanish_NonRed | v1.0 |
| Subject information and informed consent form (for publication) | L2_ICF Procedure_1_GR_English_Red | v1.0 |
| Subject information and informed consent form (for publication) | L2_ICF Procedure_1_IS_English_NonRed | 1.0 |
| Subject information and informed consent form (for publication) | L2_ICF Procedure_1_NO_English_NonRed | 01 |
| Subject information and informed consent form (for publication) | L2_ICF Procedure_1_PT_English_NonRed | 1 |
| Subject information and informed consent form (for publication) | L2_ICF Procedure_1_SE_Swedish_NonRed | 1 |
| Subject information and informed consent form (for publication) | L2_ICF Procedure_2_AT_German_Red | 1 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_1_Bulgarian_NonRed | 5 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_1_French_Red | V5.0 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_1_Hungarian_NonRed | 5.06 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_1_Italian_NonRed | 04.00 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_1_Polish_NonRed | v01 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_1_Portuguese_NonRed | 4 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_1_Romanian_NonRed | V5.0 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_1_Slovak_NonRed | V3 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_1_Spanish_NonRed | 1 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2023-508292-37-00_1_Czech_Red | 2.0 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2023-508292-37-00_2_BE_Dutch_Red | 01 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2023-508292-37-00_2_Bulgarian_Red | 1.0 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2023-508292-37-00_2_Czech_Red | 02 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2023-508292-37-00_2_English_Red | 02 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2023-508292-37-00_2_French_Red | 02 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2023-508292-37-00_2_German_Red | 02 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2023-508292-37-00_2_Greek_Red | 01 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2023-508292-37-00_2_Hungarian_Red | 02 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2023-508292-37-00_2_Icelandic_Red | 02 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2023-508292-37-00_2_Italian_Red | 02 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2023-508292-37-00_2_NL_Dutch_Red | 02 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2023-508292-37-00_2_Norwegian_Red | 01 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2023-508292-37-00_2_Polish_Red | 01 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2023-508292-37-00_2_Portuguese_Red | 02.00 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2023-508292-37-00_2_Romanian_Red | 02 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2023-508292-37-00_2_Slovak_Red | 1 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2023-508292-37-00_2_Slovenian_Red | 1.0 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2023-508292-37-00_2_Spanish_Red | 02 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2023-508292-37-00_2_Swedish_Red | 02 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Technical Language Translation_2023-508292-37-00_1_Greek_Red | 06 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Technical Language_2023-508292-37-00_1_Slovenian_Red | v3.0 |
Application history
35 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2024-03-26 | Germany | Acceptable 2024-05-03
|
2024-05-03 |
| 2 | SUBSTANTIAL MODIFICATION | SM-1 | 2024-07-12 | Germany | Acceptable 2024-10-08
|
2024-10-08 |
| 3 | NON SUBSTANTIAL MODIFICATION | NSM-1 | 2024-11-04 | Acceptable 2024-10-08
|
2024-11-04 | |
| 4 | NON SUBSTANTIAL MODIFICATION | NSM-2 | 2024-11-05 | Acceptable 2024-10-08
|
2024-11-05 | |
| 5 | NON SUBSTANTIAL MODIFICATION | NSM-3 | 2024-11-08 | Acceptable 2024-10-08
|
2024-11-08 | |
| 6 | NON SUBSTANTIAL MODIFICATION | NSM-4 | 2024-11-11 | Acceptable 2024-10-08
|
2024-11-11 | |
| 7 | NON SUBSTANTIAL MODIFICATION | NSM-5 | 2024-11-12 | Acceptable 2024-10-08
|
2024-11-12 | |
| 8 | NON SUBSTANTIAL MODIFICATION | NSM-6 | 2024-11-13 | Acceptable 2024-10-08
|
2024-11-13 | |
| 9 | NON SUBSTANTIAL MODIFICATION | NSM-7 | 2024-11-15 | Acceptable 2024-10-08
|
2024-11-15 | |
| 10 | NON SUBSTANTIAL MODIFICATION | NSM-8 | 2024-11-18 | Acceptable 2024-10-08
|
2024-11-18 | |
| 11 | SUBSTANTIAL MODIFICATION | SM-2 | 2024-11-29 | Germany | Acceptable 2025-02-06
|
2025-02-06 |
| 12 | NON SUBSTANTIAL MODIFICATION | NSM-9 | 2025-03-03 | Germany | Acceptable 2025-02-06
|
2025-03-03 |
| 13 | SUBSTANTIAL MODIFICATION | SM-3 | 2025-04-01 | Acceptable | 2025-04-11 | |
| 14 | SUBSTANTIAL MODIFICATION | SM-4 | 2025-04-02 | Acceptable | 2025-04-28 | |
| 15 | NON SUBSTANTIAL MODIFICATION | NSM-10 | 2025-04-29 | 2025-04-29 | ||
| 16 | SUBSTANTIAL MODIFICATION | SM-5 | 2025-07-17 | Germany | Acceptable 2025-10-07
|
2025-10-07 |
| 17 | SUBSTANTIAL MODIFICATION | SM-6 | 2025-10-30 | Acceptable | 2025-12-02 | |
| 18 | SUBSTANTIAL MODIFICATION | SM-7 | 2025-11-03 | Acceptable | 2025-12-22 | |
| 19 | SUBSTANTIAL MODIFICATION | SM-8 | 2025-11-12 | Acceptable | 2025-12-03 | |
| 20 | SUBSTANTIAL MODIFICATION | SM-9 | 2025-11-27 | Acceptable | 2026-03-02 | |
| 21 | SUBSTANTIAL MODIFICATION | SM-10 | 2025-12-05 | Acceptable | 2025-12-26 | |
| 22 | SUBSTANTIAL MODIFICATION | SM-11 | 2025-12-18 | Acceptable | 2026-01-27 | |
| 23 | NON SUBSTANTIAL MODIFICATION | NSM-11 | 2026-03-03 | 2026-03-03 | ||
| 24 | NON SUBSTANTIAL MODIFICATION | NSM-12 | 2026-03-03 | 2026-03-03 | ||
| 25 | NON SUBSTANTIAL MODIFICATION | NSM-14 | 2026-03-04 | 2026-03-04 | ||
| 26 | NON SUBSTANTIAL MODIFICATION | NSM-15 | 2026-03-04 | 2026-03-04 | ||
| 27 | NON SUBSTANTIAL MODIFICATION | NSM-16 | 2026-03-04 | 2026-03-04 | ||
| 28 | SUBSTANTIAL MODIFICATION | SM-12 | 2026-03-05 | Acceptable | 2026-03-12 | |
| 29 | NON SUBSTANTIAL MODIFICATION | NSM-17 | 2026-03-24 | Acceptable | 2026-03-24 | |
| 30 | SUBSTANTIAL MODIFICATION | SM-13 | 2026-03-24 | Acceptable | 2026-05-18 | |
| 31 | NON SUBSTANTIAL MODIFICATION | NSM-19 | 2026-05-26 | Acceptable 2025-10-07
|
2026-05-26 | |
| 32 | NON SUBSTANTIAL MODIFICATION | NSM-20 | 2026-05-27 | Acceptable 2025-10-07
|
2026-05-27 | |
| 33 | NON SUBSTANTIAL MODIFICATION | NSM-21 | 2026-05-28 | Acceptable 2025-10-07
|
2026-05-28 | |
| 34 | NON SUBSTANTIAL MODIFICATION | NSM-22 | 2026-05-29 | Acceptable 2025-10-07
|
2026-05-29 | |
| 35 | NON SUBSTANTIAL MODIFICATION | NSM-23 | 2026-06-01 | Acceptable 2025-10-07
|
2026-06-01 |